If you have been reading about REV-ERB agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-12. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
== Application to drugs == The hydrogen bond is relevant to drug design. According to Lipinski's rule of five the majority of orally active drugs have no more than five hydrogen bond donors and fewer than ten hydrogen bond acceptors. These interactions exist between nitrogen–hydrogen and oxygen–hydrogen centers. Many drugs do not, however, obey these "rules".
==== Brazil ==== In Brazil, during the 1990s, 7-Eleven had 17 stores in the city of São Paulo in a joint venture between Esteve S.A. Exportadora and Southland Corporation, but all closed due to high competition. In 2018, the company entered into partnership talks to operate convenience stores at gas stations operated by Petrobras Distribuidora in the country, but these did not progress further.
The Soviet Union repressed homosexuality. Even during the period when homosexuality was officially legal after the abolition of the Tsarist penal code criminalizing it, Soviet courts attempted to repress non-traditional forms of sexuality, which were widely viewed by Russian revolutionaries as a form of capitalist decadence despite more liberal views on homosexuality from Soviet academic sexologists. After Stalin's consolidation of power, homosexuality became officially recriminalised in 1934. The increased homophobia during this time interval was driven by the economic demands of the First Five-Year Plan, as well as the NKVD's view of homosexuals as "socially harmful elements", although even during this heightened period of repression, a clandestine homosexual subculture was able to persist. Homosexuality remained a criminal offence throughout the remainder of the Soviet Union's existence.
A hypobaric chamber, or altitude chamber, is a chamber used during aerospace or high terrestrial altitude research or training to simulate the effects of high altitude on the human body, especially hypoxia (low oxygen) and hypobaria (low ambient air pressure). Some chambers also control for temperature and relative humidity.
Sources: en.wikipedia.org
Somalia contains a variety of mammals due to its geographical and climatic diversity. Wildlife still occurring includes cheetah, lion, reticulated giraffe, baboon, serval, elephant, bushpig, gazelle, ibex, kudu, dik-dik, oribi, Somali wild ass, reedbuck and Grévy's zebra, elephant shrew, rock hyrax, golden mole and antelope. It also has a large population of the dromedary camel. Somalia is home to around 727 species of birds. Of these, eight are endemic, one has been introduced by humans, and one is rare or accidental. Fourteen species are globally threatened. Birds species found exclusively in the country include the Somali pigeon; Alaemon hamertoni (Alaudidae), Lesser Hoopoe-Lark; Heteromirafra archeri (Alaudidae), Archer's Lark; Mirafra ashi, Ash's Bushlark; Mirafra somalica (Alaudidae), Somali Bushlark; Spizocorys obbiensis (Alaudidae), Obbia Lark; Carduelis johannis (Fringillidae); and Warsangli Linnet. Somalia's territorial waters are prime fishing grounds for highly migratory marine species, such as tuna. A narrow but productive continental shelf contains several demersal fish and crustacean species. Fish species found exclusively in the nation include Cirrhitichthys randalli (Cirrhitidae), Symphurus fuscus (Cynoglossidae), Parapercis simulata OC (Pinguipedidae), Cociella somaliensis OC (Platycephalidae), and Pseudochromis melanotus (Pseudochromidae). There are roughly 235 species of reptiles. Of these, almost half live in the northern areas.
== Further reading == "Plates vs. Plumes: A Geological Controversy". Wiley-Blackwell. October 2010. Boschi, L.; Becker, T.W.; Steinberger, B. (2007). "Mantle plumes: Dynamic models and seismic images" (PDF). Geochemistry, Geophysics, Geosystems. 8 (Q10006): Q10006. Bibcode:2007GGG.....810006B. doi:10.1029/2007GC001733. ISSN 1525-2027. Clouard, Valérie; Gerbault, Muriel (2007). "Break-up spots: Could the Pacific open as a consequence of plate kinematics?" (PDF). Earth and Planetary Science Letters. 265 (1–2): 195. Bibcode:2008E&PSL.265..195C. doi:10.1016/j.epsl.2007.10.013. "Towards A Better Understanding Of Hot Spot Volcanism". ScienceDaily. 4 February 2008.
== Patents == Compositions and methods for inducing apoptosis. J. Kopeček, J. Yang, T.-W. Chu. (2019) US 10,251,906 B2. Compositions and methods for using albumin-based nanomedicines. J. Kopeček, J. Yang. US 10,925,973 (Feb. 23, 2021) Polymeric drug delivery conjugates and methods of making and using thereof. H. Pan, J. Yang, P. Kopečková, K. Luo, J. Kopeček (2016) US 9,289,510 B2 Hydrogels of water-soluble polymers crosslinked by protein domains. J. Kopeček, R. Stewart, K. Caldwell, C. Wang, C-H. Ho (2007) US 7,179,487 Synthetic polymeric drugs. J. Kopeček, P. Rejmanová, J. Strohalm, K. Ulbrich, B. Říhová, V. Chytrý, J.B. Lloyd, R. Duncan (1991) US 5,037,883 Copolymers based on N-substituted acrylamides, N-substituted methacrylamides and N,N-disubstituted acrylamides and the method of their manufacturing. J. Kopeček, K. Ulbrich, J. Vacík, J. Strohalm, V. Chytrý, J. Drobník, J. Kálal (1977) US 4,062,831 Device for connecting or joining the ends of interrupted tubular organs in surgical operations without stitching. D. Lím, L. Šprincl, J. Kopeček (1973) US 3,774,615 Increasing permeability of reverse osmosis membranes. J. Kopeček, S. Sourirajan (1970) US 3,536,612
Sources: en.wikipedia.org
Ian Buruma, author and journalist; board member of Human Rights in China; fellow of European Council of Foreign Relations; journalist for The New York Review of Books and has written for The Guardian; held fellowships at Wissenschaftskolleg and at Woodrow Wilson International Center for Scholars in Washington, D.C.; was Alistair Horne fellow of St Antony's College in Oxford. Stephen Bush; ( b. 1990) columnist and associate editor at the Financial Times; has written for The Guardian, The Daily Telegraph, The Jewish Chronicle, Jewish News, Times of Israel, The i Paper and New Statesman; runner-up in the Young Journalist of the Year awards category in Press Awards; was awarded Political Studies Association's Journalist of the Year award;was appointed to chair the Board of Deputies of British Jews' Commission on Racial Inclusivity in the Jewish Community. Barbara Charone author of authorised biography of Keith Richards; board member of Chelsea F.C.; journalist and music critic for the NME, Rolling Stone, Sounds magazine and Creem; public relations and press director at WEA; founded the agency MBC PR where clients include Madonna, Depeche Mode, Primal Scream, Robert Plant, Pearl Jam, Rod Stewart and Christina Aguilera as well as comedians David Walliams, Graham Norton and Russell Brand; won the Music Week Press Award in 2006 and 2009; The Guardian included her on list of "The 20 most powerful celebrity makers" as "Britain's most powerful music PR", citing her reviving of careers of Madonna and Neil Diamond and establishing Duffy and Mark Ronson. Charone is on Chelsea F.C.
== Facilities == The Aga Khan University Hospital (AKUH) is a 720-bed quaternary care teaching hospital in Karachi, Pakistan. It provides all services under one roof. The hospital offers 96 private rooms, 210 semi-private rooms, 171 general ward beds, 166 special care beds, and 77 intensive care beds across its Intensive Care Unit (ICU), Coronary Care Unit (CCU), Neonatal Intensive Care Unit (NICU) and Paediatric Intensive Care Unit (PICU). In 2019, the hospital expanded its private facilities with the opening of the Princess Zahra Pavilion, oncampus. AKUH has 17 main operating theatres, two labour and delivery operating theatres and four day-care operating theatres where day-care surgery services, including minimally invasive surgeries are offered. The hospital offers a range of diagnostic and support services, including radiology (including nuclear medicine), laboratory medicine, pharmacy, cardiopulmonary services, neurophysiology, and physiotherapy and rehabilitation medicine.
Expectations were initially very high for ketamine and esketamine for treatment of depression based on early small-scale clinical studies, with discovery of the rapid and ostensibly robust antidepressant effects of ketamine described by some authors as "the most important advance in the field of psychiatry in the past half century". According to a 2018 review, ketamine showed more than double the antidepressant effect size over placebo of conventional antidepressants in the treatment of depression based on the preliminary evidence available at the time (Cohen's d = 1.3–1.7 for ketamine, Cohen's d = 0.8 for midazolam (active placebo), and Cohen's d = 0.53–0.81 for conventional antidepressants). However, the efficacy of ketamine/esketamine for depression declined dramatically as studies became larger and more methodologically rigorous. In February 2019, an outside panel of experts recommended in a 14–2 vote that the FDA approve the nasal spray version of esketamine for treatment-resistant depression, provided that it be given in a clinical setting, with people remaining on site for at least two hours after. The reasoning for this requirement is that trial participants temporarily experienced sedation, visual disturbances, trouble speaking, confusion, numbness, and feelings of dizziness immediately after. The approval of esketamine for treatment-resistant depression by the FDA was controversial due to limited and mixed evidence of efficacy and safety. In January 2020, esketamine was rejected by the National Health Service (NHS) of Great Britain.
== Factors that affect distribution == There are many factors that affect a drug's distribution throughout an organism, but Pascuzzo considers that the most important ones are the following: an organism's physical volume, the removal rate and the degree to which a drug binds with plasma proteins and / or tissues.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.